1. Home
  2. ARDX vs IMTX Comparison

ARDX vs IMTX Comparison

Compare ARDX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.12

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Immatics N.V.

IMTX

Immatics N.V.

HOLD

Current Price

$9.22

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDX
IMTX
Founded
2007
N/A
Country
United States
Germany
Employees
N/A
407
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ARDX
IMTX
Price
$5.12
$9.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
$15.14
$19.00
AVG Volume (30 Days)
4.7M
345.9K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,607,000.00
N/A
Revenue This Year
$37.75
N/A
Revenue Next Year
$34.24
$25.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.08
$5.05
52 Week High
$8.40
$12.41

Technical Indicators

Market Signals
Indicator
ARDX
IMTX
Relative Strength Index (RSI) 38.21 41.39
Support Level $4.89 $8.98
Resistance Level $5.34 $10.67
Average True Range (ATR) 0.21 0.52
MACD -0.01 -0.02
Stochastic Oscillator 30.40 7.84

Price Performance

Historical Comparison
ARDX
IMTX

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: